SCHEMBL7174602

SCHEMBL7174602

O=C(Pc1ccc(-c2ccccc2)cc1)c1c(C(F)(F)F)cccc1C(F)(F)F.[LiH]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.39
EPHX2 P34913 2/20 0.38
KIF11 P52732 1/20 0.38
CYP2C9 P11712 1/20 0.38
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
SCN9A Q15858 1/20 0.36
PTPN5 P54829 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC4 P56524 1/20 0.35
LDHA P00338 1/20 0.35
SLC13A5 Q86YT5 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 2/20 0.35
PPARG P37231 1/20 0.35
RORC P51449 1/20 0.35
ABCC4 O15439 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189867 0.91 HDAC4 (0.39) FABP4RXRARXRBRXRGHDAC4
SCHEMBL7188798 0.84 MAPK14 (0.40) EPHX2NR1H2NR1H3MEN1KMT2A
SCHEMBL7184683 0.83 MEN1 (0.39) CYP2C9HDAC4LMNAHTTMEN1
SCHEMBL7175221 0.79 SLC13A5 (0.39) FABP4SCN9ASLC13A5LMNAGAA
SCHEMBL7180687 0.79 MAOB (0.45) EPHX2LMNAGAAMEN1RAB9A
SCHEMBL7182230 0.79 RXRA (0.47) RXRARXRBRXRGHDAC6LMNA
SCHEMBL7182551 0.78 LMNA (0.45) FABP4LMNAGAAABCC4TSHR
SCHEMBL7187567 0.77 MAPK8 (0.35) LMNAGAAPPARGMEN1POLB
Lithium SCHEMBL7175228 0.77 SLC13A5 (0.39) FABP4SCN9ASLC13A5LMNAGAA
SCHEMBL7183770 0.76 FABP3 (0.40) FABP4LMNAGAAABCC4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FABP4 4550/4885EPHX2 2476/4885KIF11 719/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FABP4 4256/4885EPHX2 2048/4885KIF11 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.